128 related articles for article (PubMed ID: 7886270)
1. Persistent GHRH-induced PRL secretion in Cushing's syndrome, obesity and exogenous hypercortisolism.
Cordido F; Peino R; Martínez-Ramonde T
Rev Esp Fisiol; 1994 Sep; 50(3):139-43. PubMed ID: 7886270
[TBL] [Abstract][Full Text] [Related]
2. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
[TBL] [Abstract][Full Text] [Related]
4. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
[TBL] [Abstract][Full Text] [Related]
5. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
6. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
[TBL] [Abstract][Full Text] [Related]
7. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
[TBL] [Abstract][Full Text] [Related]
9. Effects of sumatriptan on growth hormone releasing hormone-stimulated growth hormone secretion in acromegaly.
Cuttica CM; Sessarego P; Ponzani P; Falivene MR; Valenti S; De Martini D; Giusti M
Recenti Prog Med; 1997 Jun; 88(6):264-8. PubMed ID: 9233053
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index.
van Aken MO; Pereira AM; Frölich M; Romijn JA; Pijl H; Veldhuis JD; Roelfsema F
Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E63-70. PubMed ID: 15328071
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
Tzanela M; Zianni D; Stylianidou Ch; Karavitaki N; Tsagarakis S; Thalassinos NC
Clin Endocrinol (Oxf); 2005 May; 62(5):597-602. PubMed ID: 15853831
[TBL] [Abstract][Full Text] [Related]
12. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
[TBL] [Abstract][Full Text] [Related]
13. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
Clin Endocrinol (Oxf); 2000 May; 52(5):625-32. PubMed ID: 10792343
[TBL] [Abstract][Full Text] [Related]
15. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus.
Köller MD; Templ E; Riedl M; Clodi M; Wagner O; Smolen JS; Luger A
Ann Rheum Dis; 2004 Dec; 63(12):1677-80. PubMed ID: 15082470
[TBL] [Abstract][Full Text] [Related]
16. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
Robaczyk MG
Ann Acad Med Stetin; 2002; 48():283-300. PubMed ID: 14601484
[TBL] [Abstract][Full Text] [Related]
18. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states.
Pecori Giraldi F; Pivonello R; Ambrogio AG; De Martino MC; De Martin M; Scacchi M; Colao A; Toja PM; Lombardi G; Cavagnini F
Clin Endocrinol (Oxf); 2007 Feb; 66(2):251-7. PubMed ID: 17223996
[TBL] [Abstract][Full Text] [Related]
19. Regulation of prolactin secretion in patients with Cushing's disease. A comparative study on the effects of dexamethasone, lysine vasopressin and ACTH on prolactin secretion by the rat pituitary gland in vitro.
Lamberts SW; de Quijada M; Visser TJ
Neuroendocrinology; 1981 Mar; 32(3):150-4. PubMed ID: 6261178
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic-pituitary function in Cushing's disease.
Le Roith D; Shapiro MS; Gutman A; Spitz IM
J Endocrinol Invest; 1979; 2(4):379-83. PubMed ID: 119799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
